Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryViva Health Dysport Coverage Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0239

    Dysport® (abobotulinumtoxinA) — Coverage Criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0239 alerts

    Get alerted when Policy IC-0239 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, indications, and renewal criteria for Dysport (abobotulinumtoxinA) for Viva Health members receiving intramuscular, intradetrusor, or intradermal injections.

    Policy Summary
    PayerViva Health
    PolicyDysport® (abobotulinumtoxinA) — Coverage Criteria
    Policy CodePolicy IC-0239
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization; initial approvals valid for 6 months with standard renewals every 12 months and dosing limits per indication must be met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 moinitial prior authorization duration
    12 morenewal prior authorization duration
    200max units per dose (cervical dystonia)
    84 daystypical dosing interval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J0586
    HCPCS billing code
    18+minimum age (most indications)

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    Universal criteria: Member is at least 18 years of age (unless otherwise specified); member does NOT have any FDA-labeled contraindications to the requested agent (e.g., hypersensitivity to any botulinum toxin product or excipients, hypersensitivity to cow's milk protein, active infection at the proposed injection site); member is not on concurrent treatment with another botulinum toxin;age >=18 when not otherwise specified

    From Universal Criteria and Initial Approval

    Cervical Dystonia specific: Member has a history of recurrent involuntary contraction of one or more muscles in the neck and upper shoulders AND either sustained head tilt OR abnormal posturing with limited range of motion in the neck

    Chunk 6

    Spastic conditions: Member has upper or lower limb spasticity (adult) OR pediatric upper/lower limb spasticity in members at least 2 years of age OR hemifacial spasmpediatric >=2 years for pediatric spasticity

    Chunk 7

    Chronic migraine prophylaxis: Physician-assessed baseline disease severity using an objective tool (e.g., HIT-6, MHD, MIDAS, MPFID); member is utilizing prophylactic intervention modalities; other causes of headache ruled out; diagnosis of chronic migraine defined as >=15 headache days/month for >3 months AND on >=8 days/month for >3 months headaches have migraine features (relief by triptans/ergots OR aura OR migraine characteristics)>=15 days/month; >=8 days/month with migraine features

    Chunk 9

    Sialorrhea associated with neurological disorders: History of troublesome sialorrhea for at least a 3-month period AND member has Parkinson's disease OR severe developmental delays OR cerebral palsy>=3 months

    Chunk 10

    Chronic anal fissure: Other causes of disease ruled out; failed non-pharmacologic supportive measures; failed >=1 month trial of conventional pharmacologic therapy (e.g., topical/oral nifedipine, diltiazem, topical nitroglycerin, bethanechol)>=1 month pharmacologic trial

    Chunk 11

    Neurogenic detrusor overactivity (NDO): Detrusor overactivity associated with a neurologic condition confirmed by urodynamic testing AND failed a 1 month or longer trial of two medications from either the antimuscarinic or beta-adrenergic classesfailed 2 medications, each >=1 month

    Chunk 12

    Overactive bladder (OAB): Symptoms of urge urinary incontinence, urgency, and frequency AND failed a 1 month or longer trial of two medications from either the antimuscarinic or beta-adrenergic classesfailed 2 medications, each >=1 month

    Chunk 13

    Severe primary axillary hyperhidrosis: Failed >=1 month trial of a topical agent AND either history of medical complications (e.g., skin infections) OR significant functional impairment/impact on activities of daily living>=1 month topical trial

    Chunk 14

    Severe palmar hyperhidrosis: Failed >=1 month trial of a topical agent AND failed iontophoresis AND either history of medical complications OR significant impact on activities of daily living>=1 month topical trial

    Chunk 15

    Ventral hernia (preoperative use): Member has a large ventral hernia with loss of domain or contaminated ventral hernia AND Dysport is used preoperatively in members scheduled to receive abdominal wall reconstruction (AWR)preoperative use for AWR

    Chunk 16

    Continuation Therapy / Renewal

    Renewal covered when ALL of the following are met:

    Continued eligibility: Member continues to meet universal and indication-specific criteria; duration of authorization has not been exceeded; absence of unacceptable toxicity (examples include symptoms of toxin spread such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, breathing difficulties; or serious hypersensitivity reactions); disease response demonstrated per indication

    Chunk 17

    Blepharospasm response: Improvement of severity and/or frequency of eyelid spasms

    Chunk 18

    Cervical dystonia response: Improvement in the severity and frequency of pain AND improvement of abnormal head positioning

    Chunk 19

    Blepharospasm - Continued/Response Criteria

    Covered when ALL of the following are met

    Blepharospasm response: Improvement of severity and/or frequency of eyelid spasmsobjective or documented clinical improvement

    Chunk 18

    Cervical Dystonia - Continued/Response Criteria

    Covered when ALL of the following are met

    Cervical dystonia response: Improvement in the severity and frequency of pain AND improvement of abnormal head positioningdocumented clinical improvement

    Chunk 19

    Upper/Lower Limb Spasticity - Response Criteria

    Covered when ALL of the following are met

    Spasticity response: Decrease in tone and/or resistance of affected areas based on a validated measuring tool (e.g., Ashworth Scale, Physician Global Assessment, Clinical Global Impression [CGI])measured improvement on validated tool

    Chunk 20

    Severe Primary Axillary/Palmar Hyperhidrosis - Response Criteria

    Covered when ALL of the following are met

    Axillary hyperhidrosis response: Significant reduction in spontaneous axillary sweat production AND member has a significant improvement in activities of daily livingobjective reduction and ADL improvement

    Chunk 21

    Palmar hyperhidrosis response: Significant reduction in spontaneous palmar sweat production AND member has a significant improvement in activities of daily livingobjective reduction and ADL improvement

    Chunk 22

    Chronic Migraine Prophylaxis - Response Criteria

    Covered when ALL of the following are met

    Chronic migraine response: Significant decrease in number, frequency, and/or intensity of headaches compared to baseline on an objective measure/tool (e.g., HIT-6, MHD, MIDAS, MPFID); improvement in function; AND member continues to utilize prophylactic intervention modalitiesdocumented reduction in MHD or validated tool scores

    Chunk 23

    Sialorrhea associated with Neurological Disorders - Response Criteria

    Covered when ALL of the following are met

    Sialorrhea response: Significant decrease in saliva productiondocumented reduction in saliva production

    Chunk 24

    Detrusor Overactivity / Overactive Bladder - Response Criteria

    Covered when ALL of the following are met

    Incontinence due to detrusor overactivity: Significant improvements in weekly frequency of incontinence episodes AND member's post-void residual (PVR) periodically assessed as medically appropriatereduction in incontinence frequency and documented PVR monitoring

    Chunk 25

    Overactive bladder response: Significant improvement in daily frequency of urinary incontinence or micturition episodes and/or volume voided per micturition AND member's post-void residual (PVR) periodically assessed as medically appropriatedocumented improvement and PVR monitoring

    Chunk 26

    Hemifacial Spasm - Response Criteria

    Covered when ANY of the following are met

    Hemifacial spasm response: Decrease in frequency and/or severity of spasm, OR decrease in tone and/or improvement in facial asymmetry on the affected sidedocumented symptomatic improvement

    Chunk 27

    Chronic Anal Fissure - Response Criteria

    Covered when ANY of the following are met

    Anal fissure response: Complete healing of anal fissure OR symptomatic improvement of persistent fissuresdocumented healing or symptomatic improvement

    Chunk 28

    Prior authorization is required for Dysport (abobotulinumtoxinA). Initial prior authorization is valid for 6 months (180 days), and standard renewals are available every 12 months (365 days) thereafter unless the policy specifies otherwise. For the indication of ventral hernia used preoperatively for abdominal wall reconstruction, prior authorization validity may NOT be renewed (preoperative use only) and should be requested only for the documented preoperative period.

    Units of Dysport are specific to its preparation and assay method and are not interchangeable with units of other botulinum toxin products. Do not convert Dysport units to units of other botulinum toxin formulations when documenting doses or submitting claims.

    Coding and Dosing Limits

    Max Units (per dose and over time) [HCPCS Unit]HCPCS
    Cervical Dystonia: Billable Units = 200Cervical Dystonia, Billable Units = 200. Per # days = 200 every 84 days
    Chronic Migraine Prophylaxis: Billable Units = 60Chronic Migraine Prophylaxis, Billable Units = 60. Per # days = 84
    Sialorrhea: Billable Units = 100Sialorrhea, Billable Units = 100. Per # days = 84
    Chronic Anal Fissure: Billable Units = 60Chronic Anal Fissure, Billable Units = 60. Per # days = 84
    Blepharospasms: Billable Units = 60Blepharospasms, Billable Units = 60. Per # days = 84
    Upper Limb Spasticity: Billable Units = 200Upper Limb Spasticity, Billable Units = 200. Per # days = 84
    Lower Limb Spasticity: Billable Units = 300Lower Limb Spasticity, Billable Units = 300. Per # days = 84
    Neurogenic Detrusor Overactivity/OAB: Billable Units = 160Neurogenic Detrusor Overactivity/OAB, Billable Units = 160. Per # days = 84
    Severe Primary Axillary Hyperhidrosis: Billable Units = 100Severe Primary Axillary Hyperhidrosis, Billable Units = 100. Per # days = 84
    Palmar Hyperhidrosis: Billable Units = 100Palmar Hyperhidrosis, Billable Units = 100. Per # days = 168
    1–10 of 12
    1/2
    HCPCS CodesHCPCSCovered
    J0586Injection, abobotulinumtoxina, 5 units; 1 billable unit = 5 units
    NDCsNDC
    15054-0530-xxDysport 300 unit powder for injection; single-dose vial
    15054-0500-xxDysport 500 unit powder for injection; single-dose vial
    Covered ICD-10 Codes (selection start)ICD-10Covered
    G11.4Hereditary spastic paraplegia
    G24.3Spasmodic torticollis
    G24.5Blepharospasm
    G35.ARelapsing-remitting multiple sclerosis
    G35.B0Primary progressive multiple sclerosis, unspecified
    G35.B1Active primary progressive multiple sclerosis
    G35.B2Non-active primary progressive multiple sclerosis
    G35.C0Secondary progressive multiple sclerosis, unspecified
    G35.C1Active secondary progressive multiple sclerosis
    G35.C2Non-active secondary progressive multiple sclerosis
    1–10 of 14
    1/2
    Covered ICD-10 Codes (continued)ICD-10Covered
    G43.719Chronic migraine without aura, intractable, with status migrainosus
    G43.E01Chronic migraine with aura, not intractable, with status migrainosus
    G43.E09Chronic migraine with aura, not intractable, without status migrainosus
    G43.E11Chronic migraine with aura, intractable, with status migrainosus
    G43.E19Chronic migraine with aura, intractable, without status migrainosus
    G51.3Clonic hemifacial spasm
    G51.31Clonic hemifacial spasm, right
    G51.32Clonic hemifacial spasm, left
    G51.33Clonic hemifacial spasm, bilateral
    G51.39Clonic hemifacial spasm, unspecified
    1–10 of 31
    1/4
    Covered ICD-10 Diagnosis CodesICD-10Covered
    I69.342Monoplegia of lower limb following cerebral infarction affecting right dominant side
    I69.343Monoplegia of lower limb following cerebral infarction affecting left dominant side
    I69.344Monoplegia of lower limb following cerebral infarction affecting right non-dominant side
    I69.349Monoplegia of lower limb following cerebral infarction affecting unspecified site
    I69.351Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side
    I69.352Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side
    I69.353Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant side
    I69.354Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side
    I69.359Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side
    I69.831Monoplegia/hemiplegia following other cerebrovascular disease
    1–10 of 45
    1/5
    Chronic migraine frequency — thresholds
    Chronic migraine definitionAt least 15 headache days per month for >3 months
    Migraine-feature days requirementOn at least 8 days per month for >3 months, headaches have migraine features (e.g., relieved by triptans/ergots, aura, or provider‑determined migraine characteristics)
    Documentation requiredPhysician-assessed baseline disease severity using objective tools (e.g., HIT‑6, MHD, MIDAS, MPFID)
    Sialorrhea duration — threshold and context
    Required minimum durationSialorrhea must be present for ≥3 months

    Provider Actions, Documentation, and Billing

    Prior Authorization

    Initial PA 6 months; renewals 12 months; age ≥18

    Prior authorization is required. Initial prior authorization validity will be provided for 6 months (180 days); standard renewals may be issued every 12 months (365 days) thereafter. Members must generally be at least 18 years of age unless an indication specifies a different minimum age (see indication-specific criteria).

    Billing Rule

    PA required; bill with HCPCS J0586

    Prior authorization is required for Dysport administration. Claims/billing should use HCPCS code J0586 (Injection, abobotulinumtoxina, 5 units; 1 billable unit = 5 units) and must conform to the policy's dosing limits and intervals for the indicated condition.

    Background

    Dysport (abobotulinumtoxinA) is administered by intramuscular, intradetrusor, or intradermal injection and is used for multiple neurologic and non‑neurologic indications. Common clinical uses include treatment of cervical dystonia, upper and lower limb spasticity (including pediatric spasticity), blepharospasm, hemifacial spasm, chronic migraine prophylaxis, sialorrhea associated with neurologic disorders, severe primary axillary or palmar hyperhidrosis, neurogenic detrusor overactivity/overactive bladder, chronic anal fissure, and select preoperative applications such as temporary abdominal muscle relaxation for ventral hernia repair. Coverage under this policy defines prior authorization, indication‑specific dosing limits, and renewal criteria for these intramuscular, intradetrusor, and intradermal uses.

    Definitions and Notes

    Compendia Recommended Indication (‡)
    Symbol meaning (‡)Indication labeled with '‡' denotes a use recommended by drug compendia
    Usage in policyCompendia‑recommended indications are identified with the ‡ symbol throughout the policy
    Interpretation for authorization‡ indicates compendia support may be considered when assessing medical necessity
    Orphan Drug (Ф)
    Symbol meaning (Ф)An indication marked with 'Ф' denotes orphan drug status per the policy
    Usage in policyOrphan drug indications are flagged with the Ф symbol in indication listings
    Implication
    Policy Summary
    PayerViva Health
    PolicyDysport® (abobotulinumtoxinA) — Coverage Criteria
    Policy CodePolicy IC-0239
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization; initial approvals valid for 6 months with standard renewals every 12 months and dosing limits per indication must be met.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dosing LimitsProvider Actions, Documentation, and BillingBackgroundDefinitions and Notes
    Associated disordersSialorrhea must be associated with neurological disorders such as Parkinson disease, severe developmental delays, or cerebral palsy
    Response documentationRenewal requires documented significant decrease in saliva production
    Dosing maxima and intervals — indication summaries
    Cervical dystoniaInitial: 500 units divided among affected muscles; re‑treatment: 250–1,000 units every ≥12 weeks
    Upper limb spasticity (adults)500–1,000 units every 12–16 weeks; max total per session (upper+lower) in adults = 1,500 units
    Chronic migraineUp to 240 units every 12 weeks
    SialorrheaUp to 450 units every 12 weeks
    Neurogenic detrusor overactivity (NDO)Up to 750 units every 12 weeks
    Axillary hyperhidrosisUp to 200 units per axilla no more often than every 12 weeks
    Pediatric spasticityPediatrics: up to 30 units/kg or 1,000 units per 3‑month interval (whichever is lower); lower‑limb session limits also specified by kg thresholds
    CMS LCA effective date — citation
    CMS LCAs citedMultiple Local Coverage Articles for botulinum toxin injections are cited in references (National Government Services, Noridian, WPS, CGS, Palmetto GBA)
    Effective date noted in LCAsEffective date cited for multiple Local Coverage Articles: 04/09/2026
    Reference detailsLCAs listed include A59707, A57186, A59809, A59726, A57185, A59714 with updates in April 2026
    Dual coding rule — billing requirement
    Dual coding requirementPrimary G and M diagnosis codes require a secondary G or I code in order to be payable
    Potential denial triggerClaims using primary G and M codes without the required secondary G or I code may be denied
    Billing code contextEnsure appropriate secondary diagnosis coding when submitting claims for Dysport (see Appendix/LCAs for coding guidance)
    Note

    NQTL factors considered for PA

    Prior authorization was applied after assessing Non‑Quantitative Treatment Limitation (NQTL) factors including the clinical indication, safety and efficacy, potential for misuse/abuse, and drug cost; these factors informed the decision to require PA.

    • NQTL factors considered: Indication (Yes), Safety/efficacy (Yes), Potential for misuse/abuse (No), Cost (Yes)
    Note

    Follow CMS manuals and applicable NCDs/LCDs/LCAs

    For Medicare beneficiaries, follow CMS guidance: the Medicare Benefit Policy Manual and any applicable National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs). Compliance with NCDs/LCDs/LCAs is required where applicable.

    • Use CMS Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 as applicable.
    • Search the CMS Coverage Database for relevant NCD/LCD/LCA documents.
    Prior Authorization

    Document required prior therapy trials and failures

    Before approval, document trials and failures of required non‑surgical or pharmacologic therapies specific to the indication (examples provided by indication).

    • Severe axillary hyperhidrosis: failed ≥1 month trial of a topical agent.
    • Severe palmar hyperhidrosis: failed ≥1 month topical trial and failed iontophoresis.
    • Chronic anal fissure: failed non‑pharmacologic measures and ≥1 month trial of conventional pharmacologic therapy.
    • NDO/OAB: failed 1+ month trials of two medications from antimuscarinic or beta‑adrenergic classes.
    Documentation Required

    Continue other prophylactic modalities for chronic migraine

    For chronic migraine prophylaxis, continue other prophylactic interventions as part of ongoing management when administering Dysport.

    • Examples: pharmacotherapy, behavioral therapy, neuromodulation, trigger avoidance, physical therapy.
    Step Therapy

    No explicit step‑therapy algorithm in policy (NQTL assessed)

    The policy considered NQTL factors (indication, safety/efficacy, cost) when requiring PA, but it does not prescribe a specific step‑therapy algorithm within the cited policy content.

    Documentation Required

    Document baseline objective migraine severity (HIT‑6, MHD)

    For chronic migraine prophylaxis PA requests, include baseline disease severity using an objective measure (e.g., HIT‑6 score or Monthly Headache Days) to document the need for therapy.

    • Baseline objective measures: HIT‑6, monthly headache days (MHD), MIDAS, or MPFID.
    Documentation Required

    Record baseline and post‑treatment outcomes with validated tools

    Document baseline and post‑treatment outcomes using validated tools appropriate to the indication (examples include HIT‑6, MHD, MIDAS for migraine; Ashworth Scale for spasticity; CGI/Physician Global Assessment where applicable).

    • Migraine: HIT‑6, MHD, MIDAS, MPFID and functional improvement.
    • Spasticity: Ashworth Scale, CGI, or Physician Global Assessment showing decreased tone.
    • Incontinence/OAB: documented change in incontinence frequency and periodic PVR assessment.
    Billing Rule

    Follow cited CMS Local Coverage Articles for botulinum toxin billing

    Providers should follow the cited Medicare Local Coverage Articles (LCAs) and billing/coding guidance for botulinum toxin injections when billing claims.

    • Several LCAs are cited (see references) with effective date 04/09/2026 for billing/coding guidance.
    Billing Rule

    Use covered ICD‑10 codes from Appendix 1 on claims

    Use diagnosis codes listed in Appendix 1 for claims. Appendix 1 contains the covered ICD‑10 codes and examples (e.g., G43.* for chronic migraine, I69.* post‑cerebrovascular codes, K60.1 for chronic anal fissure).

    • Appendix 1 lists covered ICD‑10 codes that should be used on claims for Dysport.
    Denial Risk

    Denial risk: FDA‑labeled contraindications & concurrent botulinum toxin

    Requests may be denied if the member has FDA‑labeled contraindications (e.g., hypersensitivity to any botulinum toxin product or excipients, hypersensitivity to cow's milk protein, active infection at the proposed injection site) or if the member is receiving concurrent treatment with another botulinum toxin.

    Denial Risk

    Denial trigger: insufficient objective outcome documentation

    Authorization requests lacking the policy‑specified objective outcome documentation for the condition (e.g., improvement in eyelid spasm for blepharospasm, reduction in monthly headache days or HIT‑6/MIDAS improvement for chronic migraine, validated spasticity scale improvement for spasticity) may be denied.

    • Denials may be triggered by absence of documented symptomatic or objective improvement per indication‑specific response criteria.
    Prior Authorization

    PA consideration: indication, safety/efficacy, cost

    Prior authorization may be applied because of the drug's indication, safety/efficacy considerations, and its cost, per the NQTL factor assessment.

    Billing Rule

    Dual coding required for primary G/M diagnosis codes

    Claims using primary G and M diagnosis codes without the required secondary G or I code may be denied; ensure dual‑coding requirements are met when submitting claims with primary G/M codes.

    • Primary G and M codes require a secondary G or I code to be payable.
    Ф indicates the product has orphan designation relevant to that indication
    Unit equivalency note
    Unit non‑equivalence statementUnits of Dysport are specific to its preparation and assay method and are not interchangeable with units of other botulinum toxin products
    Conversion warningUnits cannot be compared to or converted into units of any other botulinum toxin product
    Billing implicationClaims and dosing must use Dysport units (HCPCS/J0586 billing reflects Dysport unitization)
    Non-Quantitative Treatment Limitation (NQTL) — definition
    NQTL definitionNon‑quantitative treatment limitations (NQTLs) are methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided (e.g., utilization review or prior authorization)
    Examples consideredExamples include utilization review, prior authorization, and standards applied to MH/SUD versus M/S benefits
    Policy applicationThe NQTL checklist was used to assess indication, safety/efficacy, misuse potential, and cost when designing PA criteria